MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 12.02.2026
Eli Lilly and Company Gesamtverbindlichkeiten 2011-2026 | LLY
Gesamtverbindlichkeiten Jährlich Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 36.6 B | 33 B | 33.3 B | 24.7 B | 21 B | 21.8 B | 17.6 B | 19.6 B | 20.1 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 36.6 B | 17.6 B | 25.3 B |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 4.73 | 0.42 % | $ 761 M |  Britain |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 333.39 | -1.77 % | $ 43.7 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.17 | 3.93 % | $ 5.22 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
35 M | $ 7.42 | -15.1 % | $ 73.3 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 21.68 | 1.4 % | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 3.4 | 4.29 % | $ 342 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 99.47 | 1.08 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
32.5 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | - | - | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.24 | 2.17 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.58 | -2.03 % | $ 3.13 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.49 | 0.68 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
5.68 M | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 33.87 | 1.62 % | $ 2.25 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
49.9 M | - | - | $ 25.3 M | USA |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |